Viral resistance in HCV infection

Publication date: October 2018Source: Current Opinion in Virology, Volume 32Author(s): Francesca Ceccherini-Silberstein, Valeria Cento, Velia Chiara Di Maio, Carlo Federico Perno, Antonio CraxìThe introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of>95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review explores in detail the aspects of HCV innate and treatment-induced resistance to new interferon-free DAA regimens.

Source: Current Opinion in Virology - November 14, 2018 Category: Virology Source Type: research